Navigation Links
Research shows early promise of new drug for cancers caused by viruses
Date:1/14/2014

New Orleans, LA Christopher Parsons, MD, Director of the HIV Malignancies Program at LSU Health Sciences Center New Orleans, is the senior author of a paper that is the first to report that specialized fat (lipid) molecules, called sphingolipids, play a key role in the survival of aggressive lymphomas caused by viruses. The paper also reveals a new therapy for preventing production of sphingolipids by lymphoma cells, thereby killing these cells, which are often resistant to standard therapies. The study is published in the January 2014 issue of Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.

The research team focuses on primary effusion lymphoma (PEL), an aggressive and deadly variant of diffuse large B-cell lymphoma that frequently occurs in people infected with HIV. Though scientists have known that the Kaposi's sarcoma-associated herpesvirus (KSHV) causes PEL, development of effective therapies has proven difficult. PEL tumors arise within body cavities and progress rapidly with an average survival of around 6 months. Combination chemotherapy represents the current standard of care for PEL, but side effects (including bone marrow suppression) and drug resistance (generated through virus-associated mechanisms) continue to limit the effectiveness of standard therapy.

After documenting the role of an enzyme called sphingosine kinase (SK), in the generation of biologically active sphingolipids in PEL tumors that keep the tumor cells alive, the researchers tested a novel clinical-grade small molecule that selectively targets SK. The molecule, called ABC294640, was developed by Apogee Biotechnology Corporation. Previous studies found antitumor effects for ABC294640 with kidney, prostate, and breast cancer cell lines. In the current study, ABC294640 not only inhibited SK function and induced PEL cell death, it worked selectively for virus-infected cells while sparing uninfected cells.

"It is still early in our understanding of how these special lipids contribute to viral cancers, but this is a major potential advance. There are no therapies available to fight viral tumors by selectively blocking these pathways, all while not harming normal, uninfected cells," notes Dr. Parsons, who is also a member of the LSUHSC Stanley S. Scott Cancer Center.

Dr. Parsons' research group partnered with Apogee several years ago to develop and test new small molecules targeting lipid synthesis pathways, especially those in viral lymphomas, which have high rates of relapse or failure with standard therapies and higher mortality than non-viral lymphomas.

"Our research thus far indicates that this molecule is safe, with the potential to stand alone as a single, orally administered drug with no need to combine it with other toxic drugs now routinely used but which fail to work for many patients," concludes Dr. Parsons.


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Related medicine news :

1. UNC researchers harness suns energy during day for use at night
2. T-cell research sheds light on why HIV can persist despite treatment
3. Global Medical Publishing Market 2014-2018: Worldwide Industry Share, Investment Trends, Growth, Size, Strategy and Forecast Research Report
4. Research for Her TM, an online clinical research registry, honored with distinguished national award
5. Its all coming back to me now: Researchers find caffeine enhances memory
6. Personalized Medicine in Oncology Partnering Terms and Agreements, a New Research Report at ReportsnReports.com
7. Eye Glasses & Contact Lens Stores in the US Industry Market Research Report from IBISWorld Has Been Updated
8. Global Ostomy Care Industry Trend & 2017 Opportunities Analyzed in New Research Study at MarketReportsOnline.com
9. China Digital Radiography Industry & Global CBCT Market Analysis in a New Research Study Available at DeepResearchReports.com
10. Loyola receives Innovation Award for clinical research database
11. CardioWise™ Completes Small Business Innovation and Research Grant from the National Science Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 2017 , ... “I Forgive You”: a fine examination of how God handles sin, including ... of published author, Stephen Miller, who, for over ten long years has been waiting to ... in Trinidad and Tobago, he has been serving the Lord for over twenty years, and ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Land of More and More”: ... issue of world hunger, and shares the simple and achievable answer. “The Land of ... member of the Fairview Missionary Church in Angola, Indiana where he works with the ...
(Date:1/19/2017)... ... January 19, 2017 , ... Wells ... facility enhancement of their 503A compounding pharmacy located in Ocala, Florida. , ... physicians and patients throughout the United States for high-quality human anti-aging and ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... telemedicine solutions, has recently unveiled impressive transportable capabilities with their iMedHD2™ Portable ... is an extension to RMT technology that delivers HD, dynamic, streaming ultrasound images ...
(Date:1/19/2017)... ... 2017 , ... MB Business Capital, a division of MB ... to Sunrise, Florida-based Management Health Systems, LLC, dba MedPro Healthcare Staffing (“MedPro”). Proceeds ... MedPro led by Harren Equity Partners. Brightwood Capital Advisors provided a new ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017 Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase ... The global anti-obesity drugs market is expected to ... the forecast period and CAGR of 38.7% in the second half ... a CAGR of 32.8% from 2016 to 2027. The market is ... $24,063 million in 2027. ...
(Date:1/19/2017)... -- James Gilbart , ... 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ...      ... in a supplement to European Oncology & Haematology ... by James Gilbart and Axel ...
(Date:1/19/2017)... ALTO, Calif. , Jan. 19, 2017   ... research, is excited to announce that the first ... Cancer Biology  (RP:CB) have been published in eLife ... this project represents the first practical evaluation of ... result in reproducible studies. Unlike other assessments of ...
Breaking Medicine Technology: